- 现金
- 17064 元
- 精华
- 12
- 帖子
- 9399
- 注册时间
- 2007-6-26
- 最后登录
- 2017-11-25
|
ARC-520 will continue development including focus on the significant market of e-antigen positive treatment-naïve chronic HBV patients. ARC-521 is being developed to target cccDNA and also, integrated DNA, which appears to be a more significant producer of HBsAg in patients who have been treated with NUCs or who are e-antigen negative. In HBeAg-negative chimps predicted to have higher levels of integrated DNA, administration of the integrant-targeted siRNA in ARC-521 led to 99% (2 logs) of additional HBsAg reduction. The Company expects to file an IND or equivalent for ARC-521 by mid-2016.
个人意见:降低表抗可以产生免疫反应,我确信,但一定要降低到很低,我认为是万分之一左右,也就是0.0001,4个数量级的降低,如果还不能激发免疫反应,就上干扰素和乙肝疫苗吧,或者古巴新药也可以,很期待arc521,同时抑制cccdna和整合dna,以大三阳患者为例,获得了99%的表抗降低,那么姑且算剩余的1%是由整合dna所产生的,那么如果可以将整合dna也抑制的程度降低到99%,那么就刚好可以达到万分之一的要求,那么激发免疫系统产生免疫反应就可以实现,所以,对于arc521,战胜乙肝,已不是不可能的了,我认为arc521至少可以解决超过50%的乙肝,加上联合用药的话,乙肝攻克只是时间问题。 |
|